<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139706</url>
  </required_header>
  <id_info>
    <org_study_id>MP-05-2019-1517</org_study_id>
    <nct_id>NCT05139706</nct_id>
  </id_info>
  <brief_title>Montreal Immune-Related Adverse Events (MIRAE) Study</brief_title>
  <acronym>MIRAE</acronym>
  <official_title>Montreal Database and Biorepository of Cancer Patients Treated With Immune Checkpoint Inhibitors for the Study of Immune-related Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting&#xD;
      cancer. However, a substantial percentage of patients experience off-target adverse effects&#xD;
      in the form of mild to severe inflammation in different organs, commonly called&#xD;
      immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be&#xD;
      life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no&#xD;
      reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study&#xD;
      collects clinical information and biospecimens (blood, tissue, stool) from cancer patients&#xD;
      treated with ICI to facilitate research on the identification of predictive biomarkers of&#xD;
      irAEs, their causes, and the design of effective management strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      During cancer development and progression, cancer cells evolve to evade natural anti-tumor&#xD;
      immunity. One major pathway of immune evasion involves the engagement of co-inhibitory&#xD;
      receptors present on the surface of T cells that modulate their activation status, and&#xD;
      therefore their ability to directly or indirectly kill tumor cells. These receptors are known&#xD;
      as immune checkpoint inhibitors (ICI). Blockade of ICI using antibodies leads to prolonged T&#xD;
      cell activation and unleashes the anti-tumor activity of T cells. ICI treatment for cancer&#xD;
      has led to unprecedented advances in cancer treatment by prolonging survival of patients with&#xD;
      previously refractory cancers. Among these ICI, CTLA-4, PD-1 and PDL-1 inhibitors have been&#xD;
      shown to be effective cancer immunotherapies, and many other ICIs are now in pre-clinical and&#xD;
      clinical development.&#xD;
&#xD;
      Although ICI cancer therapy is overall well tolerated, off-target immune reactions targeting&#xD;
      healthy cells or tissues called immune-related adverse events (irAEs) develop in a&#xD;
      substantial percentage of patients limiting the use of ICI therapy. irAEs target range from&#xD;
      mild to severe and fatal. Currently, there are no reliable predictive biomarkers for the wide&#xD;
      spectrum of irAEs and their clinical management in severe cases involves discontinuation of&#xD;
      ICI therapy.&#xD;
&#xD;
      The Montreal Immune-Related Adverse Events (MIRAE) study is a biobank that collects human&#xD;
      biological specimens (e.g., tissue, blood, plasma, PBMCs, saliva, stool) and the associated&#xD;
      clinical information from cancer patients treated with ICI with the purpose of promoting&#xD;
      research to identify clinical and biological predictors and mechanisms of irAEs, evaluate the&#xD;
      effects of immunomodulatory treatment of irAEs on tumor biology, and investigate treatment&#xD;
      strategies to minimize irAEs.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Identify biomarkers predictive of irAEs, including cellular, immunologic, genetic and&#xD;
           microbial biomarkers; and&#xD;
&#xD;
        2. Evaluate the effects of immunomodulatory treatment of irAEs, and investigate treatment&#xD;
           strategies that minimize irAEs and maximize ICI efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of immune-related adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers of irAE</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cancer</condition>
  <condition>Immune System Disorder</condition>
  <condition>Inflammatory Reaction</condition>
  <condition>Autoimmune Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Whole blood&#xD;
&#xD;
        -  Peripheral blood mononuclear cells&#xD;
&#xD;
        -  Stool&#xD;
&#xD;
        -  Tissue biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients treated with ICI, patients with primary autoimmune or autoinflammatory&#xD;
        diseases and healthy volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 18 years of age&#xD;
&#xD;
          -  cancer patients treated with ICI therapy (e.g., anti-CTLA-4, anti-PD-1, anti-PD-L1,&#xD;
             and combinations)&#xD;
&#xD;
          -  patients with primary autoimmune or autoinflammatory diseases that resemble&#xD;
             immune-related adverse events (irAEs)&#xD;
&#xD;
          -  healthy volunteers with non-inflammatory disorders, and without any history of cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants not able to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Hudson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital, McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Hudson, MD</last_name>
    <phone>1-514-340-8222</phone>
    <phone_ext>23476</phone_ext>
    <email>marie.hudson@mcgill.ca, marie.hudson.med@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Flores, PhD</last_name>
    <phone>1-514-677-8155</phone>
    <email>Manuel.Flores.Molina.ccomtl@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Hudson, MD MPH</last_name>
      <phone>1-514-340-8222</phone>
      <phone_ext>23476</phone_ext>
      <email>marie.hudson@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Flores, PhD</last_name>
      <phone>1-514-677-8155</phone>
      <email>Manuel.Flores.Molina.ccomtl@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Marie Hudson, MD</investigator_full_name>
    <investigator_title>Marie Hudson, MD MPH FRCPC Principal Investigator, Rheumatologist, Division of Rheumatology and Department of Medicine, Jewish General Hospital and McGill University</investigator_title>
  </responsible_party>
  <keyword>irAEs</keyword>
  <keyword>ICI (ICB)</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL-1</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Cemiplimab</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Avelumab</keyword>
  <keyword>Durvalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

